Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report

BACKGROUND: Tumor lysis syndrome is a rare and potentially fatal complication of oncologic treatments, especially in solid tumors. To the best of our knowledge, tumor lysis syndrome has never been reported after trastuzumab and pertuzumab combination therapy. Knowledge of risk factors and active pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Baudon, C., Duhoux, F. P., Sinapi, I., Canon, J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911682/
https://www.ncbi.nlm.nih.gov/pubmed/27312594
http://dx.doi.org/10.1186/s13256-016-0969-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911682/
https://www.ncbi.nlm.nih.gov/pubmed/27312594
http://dx.doi.org/10.1186/s13256-016-0969-5

Ejemplares similares